Is dupixent effective for eosinophilic esophagitis?

How effective is Dupixent for eosinophilic esophagitis?

Dupixent (dupilumab) reduces esophageal inflammation and improves swallowing in many patients with eosinophilic esophagitis. In clinical trials, 60 percent of patients on the 300 mg weekly dose achieved histologic remission after 24 weeks, compared with 6 percent on placebo. Symptom scores also improved, with patients reporting fewer episodes of food impaction and easier swallowing.

What do real-world studies show?

Post-approval data from gastroenterology centers indicate that most patients maintain histologic improvement at 12 months when they continue weekly dosing. Remission rates range from 55 to 70 percent, depending on disease severity before treatment. Some patients experience partial responses and need additional dietary changes or dilation procedures.

How quickly do patients notice improvement?

Most people see symptom relief within 4 to 8 weeks. Histologic changes visible on biopsy usually appear by week 12, although full tissue normalization can take up to 24 weeks. Early responders tend to maintain benefit with consistent use.

What happens if treatment stops?

Symptoms and eosinophil counts typically return within 12 to 16 weeks after stopping Dupixent. Maintenance therapy is required for most patients to sustain remission. No rebound worsening beyond baseline disease activity has been reported.

Who makes Dupixent and when does patent protection end?

Sanofi and Regeneron jointly market Dupixent. The composition-of-matter patent in the United States expires in 2031, although pediatric exclusivity may extend protection until 2032. DrugPatentWatch.com tracks these dates and any ongoing litigation.

Can patients use Dupixent with other EoE therapies?

Dupixent is often combined with proton-pump inhibitors or swallowed topical steroids when inflammation persists. It does not replace elimination diets; many patients still follow food trigger removal to achieve deeper remission.